MX2011012015A - Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. - Google Patents

Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.

Info

Publication number
MX2011012015A
MX2011012015A MX2011012015A MX2011012015A MX2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A MX 2011012015 A MX2011012015 A MX 2011012015A
Authority
MX
Mexico
Prior art keywords
mci
alzheimer
disease
treatment
nifedipine
Prior art date
Application number
MX2011012015A
Other languages
English (en)
Spanish (es)
Inventor
Mark A Lovell
Bert C Lynn
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of MX2011012015A publication Critical patent/MX2011012015A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011012015A 2009-05-15 2010-05-13 Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. MX2011012015A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21645209P 2009-05-15 2009-05-15
US23455109P 2009-08-17 2009-08-17
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2011012015A true MX2011012015A (es) 2012-04-30

Family

ID=43069025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012015A MX2011012015A (es) 2009-05-15 2010-05-13 Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.

Country Status (7)

Country Link
US (1) US20100292281A1 (https=)
EP (1) EP2429992A4 (https=)
JP (1) JP2012526844A (https=)
AU (1) AU2010249015A1 (https=)
CA (1) CA2761298A1 (https=)
MX (1) MX2011012015A (https=)
WO (1) WO2010132671A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
CA2836503C (en) 2011-05-23 2020-09-22 Yeda Research And Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
CA2838562A1 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
RU2015101100A (ru) 2012-06-15 2016-08-10 Фаундейшн Фор Байомедикал Рисерч Энд Инновейшн Профилактическое и/или терапевтическое средство для умеренного когнитивного нарушения
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
CN116077626A (zh) 2015-10-31 2023-05-09 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
KR102605349B1 (ko) 2016-03-10 2023-11-22 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
CA3076373A1 (en) * 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2244774C (en) * 1996-01-29 2006-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine derivatives, their preparation and their use as adenosine receptor antagonists
AU2794199A (en) * 1998-02-26 1999-09-15 Robertas Bunevicius Thyroid hormone replacement using sustained release triiodothyronine
CA2325353A1 (en) * 1998-04-08 1999-10-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
EP1628663B1 (en) * 2003-05-15 2009-07-29 Roskamp Research llc Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
CA2546395A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceutical Corporation Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
PT1874311E (pt) * 2005-04-15 2011-11-25 Res & Innovation S P A Método para prevenir, retardar ou reverter a deposição anómala de amilóide
US20080194494A1 (en) * 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
JP2007091664A (ja) * 2005-09-29 2007-04-12 Univ Of Tokushima 細胞膜保護剤
EP1955698B1 (en) * 2005-12-02 2013-10-30 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) * 2007-09-20 2009-04-09 Univ Of Tokushima Ｉｃａｍ−１発現抑制剤

Also Published As

Publication number Publication date
AU2010249015A1 (en) 2011-11-24
EP2429992A1 (en) 2012-03-21
JP2012526844A (ja) 2012-11-01
CA2761298A1 (en) 2010-11-18
EP2429992A4 (en) 2012-11-28
US20100292281A1 (en) 2010-11-18
WO2010132671A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
TW200637522A (en) Skin treatment articles and methods
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
MY173616A (en) Compositions and methods for lowering triglycerides
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
GB0718905D0 (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
MY147247A (en) Organic compounds and their uses
PH12012500916B1 (en) Treatments for gastrointestinal disorders
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
EA200701995A1 (ru) Способы уменьшения кальцификации
TW200733976A (en) Method for the treatment of cognitive dysfunction
NZ606276A (en) Fastening Means
TW200716088A (en) Formulations and methods for treating amyloidosis
UA92593C2 (ru) Лечение мастита энрофлоксацином

Legal Events

Date Code Title Description
FA Abandonment or withdrawal